Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05013086
EARLY_PHASE1

177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors

Sponsor: Peking Union Medical College Hospital

View on ClinicalTrials.gov

Summary

This is an open-label, non-controlled, non-randomized study to assess the safety and measure image-based absorbed dose of 177Lu-AB-3PRGD2 in patients with Integrin αVβ3 positive tumors who will undergo radioliagnd therapy using 177Lu-AB-3PRGD2.

Official title: Therapeutic Efficiency and Response to 177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2021-10-01

Completion Date

2024-12-01

Last Updated

2024-06-13

Healthy Volunteers

No

Interventions

DRUG

1.48 GBq of 177Lu-AB-3PRGD2

accepted intravenous injection of 177Lu-AB-3PRGD2

Locations (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China